Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Begins Natural History of Disease Study for Alport Syndrome

Premium

NEW YORK (GenomeWeb) – Regulus Therapeutics announced last week that it has initiated a natural history of disease study, called ATHENA, in patients with Alport syndrome.

Alport syndrome is caused by mutations in three genes that affect production of the type IV collagen family of proteins. The result is a disruption to the structure of the glomerular basement membrane, increased expression of microRNA-21, an increase in fibrosis, and the loss of renal function, which ultimately leads to end-stage renal disease.

Regulus is developing RG-012, a miR-21 inhibitor, for the condition and aims to have it in Phase I testing next year.

Ahead of that planned trial, the company has launched ATHENA to characterize the natural decline of renal function markers such as glomerular filtration rate, creatinine, proteinuria, and beta-2 microglobulin in Alport syndrome patients over time.

The study is set to run for two years in up to 120 Alport syndrome patients. Results are expected to inform future clinical development of RG-012, the company said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.